Human CellExp™ VEGFR2/Flk-1/KDR, human recombinant

Catalog number
7399-100
Name
Human CellExp™ VEGFR2/Flk-1/KDR, human recombinant
Size
100 μg
Price
670.00 EUR
Supplier

Details

Target
VEGFR2
Background
Kinase insert domain receptor (KDR) also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF. The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Concentration
N/A
Molecular weight
This protein with 6×his tag at C-terminus, and has a calculated MW of 84.1 kDa. DTT-reduced protein migrates as 100-110 kDa protein due to glycosylation.
Synonym
KDR, CD309, FLK1, VEGFR, VEGFR2, kinase insert domain receptor
Other name
KDR, CD309, FLK1, VEGFR, VEGFR2, kinase insert domain receptor
NCBI gene number
3791
NCBI gene
VEGFR2
Gene source
Human
NCBI number
P35968
Recombinant
Yes
Source
HEK293 cells
Purification
≥95%
Tested applications
SDS-PAGE, N/A
Tested activity
N/A
Biological activity
Measured by its ability to inhibit the VEGF dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is typically 9-20 ng/ml in the presence of 5 ng/ml rhVEGF165.
Reesults
Measured by its ability to inhibit the VEGF dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is typically 9-20 ng/ml in the presence of 5 ng/ml rhVEGF165.
Binding ability
N/A
Unit
N/A
Storage condition
-20°C
Shipping under
Gel Pack
Physical appearance
Lyophilized
Physical properties
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.
How to reconstitute
Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.
Aa sequence
N/A
Before use
Centrifuge the vial prior to opening.
Notes
For Research Use Only! Not to be used in humans
Properties
Human proteins, cDNA and human recombinants are used in human reactive ELISA kits and to produce anti-human mono and polyclonal antibodies. Modern humans (Homo sapiens, primarily ssp. Homo sapiens sapiens). Depending on the epitopes used human ELISA kits can be cross reactive to many other species. Mainly analyzed are human serum, plasma, urine, saliva, human cell culture supernatants and biological samples.
Additional source
Recombinants or rec. proteins
Group
recombinants